

policy making. **METHODS:** A published decision-analysis tool (the GeDiForCETM) was employed to assess cost-effectiveness of GDM screening by comparing costs and averted disability-adjusted life years (DALYs) with no GDM screening. As modeling inputs, costs for GDM screening and antenatal care, incidence and cost of GDM perinatal adverse effects (PAE) were based on an investigation on 6 tertiary hospitals from different cities in China as part of this analysis. Cost for postpartum care was calculated based on literature and adjusted for China. PAE-DALYs, life-time cost for postpartum T2DM, and effectiveness of interventions were collected from literature. Annual discount rate was 3.0%. One-way sensitivity analyses were conducted on some key indicators. **RESULTS:** The total costs of GDM screening, intervention and life-time treatment per 1000 pregnant women were \$7,092,398 in GDM screening group, saving \$1,329,671 comparing with no screening. 277.4 DALYs were averted in screening group, which was mainly brought out by GDM postpartum care for T2DM prevention. Sensitivity analyses demonstrated robustness of the results. **CONCLUSIONS:** GDM screening and interventions are cost-saving in an urban Chinese setting by IADPSG standards. As DALYs averted mainly comes from T2DM prevention, China should pay more attention to providing postpartum care for GDM women in the future.

## PDB61

# COST OF REACHING DEFINED HBA1C TARGET USING CANAGLIFLOZIN COMPARED TO DAPAGLIFLOZIN AS ADD-ON TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN THE UNITED ARAB EMIRATES (UAE)

Schubert A<sup>1</sup>, Nielsen AT<sup>2</sup>, El Khoury A<sup>3</sup>, Kamal A<sup>3</sup>, Taieb V<sup>4</sup>

<sup>1</sup>Janssen-Cilag Poland, Warsaw, Poland, <sup>2</sup>Janssen-Cilag A/S, Birkerød, Denmark, <sup>3</sup>Janssen-Cilag, Dubai, United Arab Emirates, <sup>4</sup>Amaris, London, UK

**OBJECTIVES:** Improving glycaemic control is the primary goal of T2DM management and can help to reduce the risk of micro- and macrovascular complications. Guidelines from the American Diabetes Association and European Association for the Study of Diabetes recommend lowering HbA1c to levels <7.0% for most patients. This analysis compared the cost of reaching this target (HbA1c <7.0%) using canagliflozin versus dapagliflozin, two compounds that inhibit sodium glucose co-transporter 2 (SGLT2), in dual therapy as add-on to metformin from the payer perspective in the UAE. **METHODS:** A Bayesian network meta-analysis (NMA) was conducted to compare the efficacy of canagliflozin 100 and 300 mg versus dapagliflozin 10 mg in terms of the percentage of patients that achieved the HbA1c goal of <7.0% at 26 weeks. Based on the NMA results and the acquisition cost of dapagliflozin in the UAE (\$1.77 per day), we calculated what the daily acquisition cost of each dose of canagliflozin would be if the costs of a patient reaching the target with canagliflozin 100 and 300 mg were equalized to the cost of reaching the target with dapagliflozin 10 mg. **RESULTS:** In dual therapy as add-on to metformin, patients using canagliflozin 100 and 300 mg were more likely to achieve HbA1c <7.0% compared to those using dapagliflozin 10 mg, with odds ratios of 1.3 (Pr=82%) and 1.7 (Pr=96%), respectively. The costs of canagliflozin 100 and 300 mg that equalized the cost of reaching HbA1c <7.0% with dapagliflozin 10 mg were \$2.11 and \$2.45 per day, respectively. **CONCLUSIONS:** These results suggest that adding canagliflozin 100 or 300 mg instead of dapagliflozin 10 mg in patients inadequately controlled on metformin would result in a more efficient use of resources with costs per day up to these break-even levels.

## PDB62

# COST-EFFECTIVENESS ANALYSIS OF VILDAGLIPTIN VS. GLIMEPIRIDE AS ADD-ON TO METFORMIN IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS IN GREECE

Kousoulakou H<sup>1</sup>, Kalogeropoulou M<sup>2</sup>, Panitti E<sup>2</sup>

<sup>1</sup>University of Peloponnese, Corinth, Greece, <sup>2</sup>Novartis Hellas, Metamorfosis, Greece

**OBJECTIVES:** This study was designed to assess the cost-effectiveness of vildagliptin versus glimepiride as add-on to metformin in the management of type 2 diabetes mellitus (T2DM) patients in the Greek healthcare setting. **METHODS:** A cost-effectiveness model was designed, using MS Excel, to compare two treatment strategies. Strategy 1 consisted of first-line metformin, followed by metformin + vildagliptin in second-line, and metformin + basal insulin and metformin + basal + rapid insulin in subsequent lines. Strategy 2 differed from strategy 1 only in second-line, where metformin was administered with glimepiride. Clinical data and utilities were taken from the published literature. Only direct medical costs were included in the analysis (cost base year 2014), and consisted of drug, side-effect and comorbidity costs (taken from local officially published sources and the literature). The perspective adopted was that of the Social Insurance Fund. The time horizon was lifetime, and costs and outcomes were discounted at 3.5%. **RESULTS:** Adding vildagliptin to metformin increased drug costs compared with adding glimepiride to metformin (€2,853 vs. €2,427, respectively). However, this increase was completely offset by a decrease in the costs of associated comorbidities (€4,393 vs. €4,539) and side-effects (€3,015 vs. €3,510), resulting in a lower total cost of €214.6 in strategy 1 compared with strategy 2. Comorbidities were the largest cost component in both strategies, accounting for 42.8% and 43.3% in strategies 1 and 2, respectively. Strategy 1 was also associated with increased life-years (LYs, 0.11) and quality-adjusted life-years (QALYs, 0.11) compared with strategy 2. Strategy 1 is therefore dominant, as it is associated with both lower overall costs and increased effectiveness. **CONCLUSIONS:** Vildagliptin as add-on treatment to metformin in the management of T2DM in Greece appears to be dominant vs. glimepiride in terms of both cost per LY and cost per QALY gained.

## PDB63

# COST-EFFECTIVENESS OF SITAGLIPTIN COMPARED TO SULPHONYLUREA AS AN ADD-ON TO METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES IN GREECE

Athanasakis K<sup>1</sup>, Zhuo J<sup>2</sup>, Chen J<sup>2</sup>, Boubouchariopoulos N<sup>1</sup>, Tarantilis F<sup>1</sup>, Papageorgiou M<sup>3</sup>, Retsa P<sup>3</sup>, Brandtmüller A<sup>4</sup>, Tunceli K<sup>5</sup>, Karokis A<sup>5</sup>, Kyriopoulos J<sup>1</sup>

<sup>1</sup>National School of Public Health, Athens, Greece, <sup>2</sup>Merck & Co., Inc., North Wales, PA 19454-2505, PA, USA, <sup>3</sup>MSD Greece, Athens, Greece, <sup>4</sup>MSD, Health Outcomes & Customer Solutions, MER, Budapest, Hungary, <sup>5</sup>Merck & Co., Inc., North Wales, PA, USA

**OBJECTIVES:** Despite relevant treatments, only 29% of type 2 diabetes (T2DM) patients in Greece achieve their pre-defined glycemic targets. When treatment with metformin (MF) fails to control T2DM patients, add-on therapies are needed. Sitagliptin is indicated as second-line therapy in Greece, after treatment with MF has failed and is a valid option in the proposed national therapeutic protocols. The present study aimed to assess the cost-effectiveness of adding Sitagliptin to MF vs adding sulphonylurea (SU) to MF for the treatment of T2DM patients with inadequate glycemic control. **METHODS:** A published individual-level simulation model was developed to simulate the lifetime medical cost, diabetic complications, drug-related adverse events, life expectancy and quality adjusted life years (QALYs) associated with Sitagliptin add-on therapy versus SU add-on therapy. The model is developed based upon the UKPDS 68 risk equations to project long-term complications and mortalities. Efficacy and safety profiles of drugs were obtained from a head-to-head trial. Costs (€ 2014 prices) and effects were discounted at 3.5% annually. Greek data retrieved by an expert input forum of specialists. Sensitivity analyses performed on 17 parameters. Analysis based on Greek payer perspective. **RESULTS:** Sitagliptin strategy is projected to cost 359 EUR more than SU strategy per patient over lifetime. Sitagliptin showed reductions in diabetes-related complications and adverse events. The incremental QALY for Sitagliptin strategy is 0.042, primarily driven by the improved outcomes associated with hypoglycemia, body weight change, and MI. The incremental cost effectiveness ratio (ICER) is 8,582 €/QALY gained. Sensitivity analysis conducted varied multiple parameters. ICER ranges from 4,873 to 12,173 €/QALY gained. The results are robust and never exceeded the 30,000€/QALY threshold. **CONCLUSIONS:** Sitagliptin add-on strategy could be cost-effective, compared to SU, for the Greek healthcare setting. Furthermore, it remains cost-effective in all types of sensitivity analysis.

## PDB64

# ECONOMIC EVALUATION OF SAXAGLIPTIN IN COMBINATION WITH METFORMIN VERSUS SITAGLIPTIN OR VILDAGLIPTIN IN COMBINATION WITH METFORMIN IN PATIENTS WITH TYPE 2 DIABETES IN RUSSIA

Krysanov I<sup>1</sup>, Tiapkina M<sup>2</sup>

<sup>1</sup>Postgraduate Medical Institute, Moscow National University of Food Production, Moscow, Russia, <sup>2</sup>I.M. Sechenov First Moscow State Medical University, Moscow, Russia

**OBJECTIVES:** to assess the cost effectiveness of saxagliptin (SAXA) vs sitagliptin (SITA) or vildagliptin (VILDA) as add-on therapy to metformin (MET) in patients with type 2 diabetes mellitus (T2DM) and inadequate glycaemic control on metformin alone. **METHODS:** the Cardiff Diabetes Model was adapted to the Russian healthcare setting. We modeling events, efficacy, total costs for managing patients with T2DM: 1-st line – monotherapy metformin alone, 2-nd line (target groups) – SAXA or SITA or VILDA plus metformin, 3-nd line – insulin rescue therapy. The model simulated the disease progression and treatment effects for 40 years (8-26-6 years for 1-2-3 lines respectively). The effectiveness measure was quality-adjusted life years (QALYs) gained per patient. **RESULTS:** in case short-time efficacy (decrease HbA1c -1%) cost-effectiveness ratio (CER) for SAXA+MET was the lowest: \$835 per QALY. When compared with SITA+MET for the long-term efficacy (40 years), SAXA+MET was the dominant strategy, i.e. less costly (-\$505) and more effective (+0.16 QALY). When compared to VILDA+MET, SAXA+MET was more costly (+\$364), but more effective (+0.14 QALY). The incremental cost-effectiveness ratio (ICER) per responder for SAXA+MET vs VILDA+MET was estimated at \$2,566 per QALY gained and would be cost effective at the willingness-to-pay (WTP) threshold \$36,373/QALY for Russia in 2014. If we used combined medicines: Kombiglyce (SAXA+MET), Janumet (SITA+MET) and Galvus Met (VILDA+MET), then Kombiglyce interventions were also more efficacious than Janumet and Galvus Met, but were associated with increased total costs. The ICERs per responder for Kombiglyce were estimated at \$3,216/QALY (vs Janumet), \$3,269/QALY (vs Galvus Met) and would be cost effective at the WTP threshold \$36,373/QALY for Russia in 2014. **CONCLUSIONS:** at a willingness-to-pay threshold of \$36,373/QALY SAXA+MET and Kombiglyce is likely to be a cost-effective option for the treatment of T2DM in adult patients in Russia.

## PDB65

# ECONOMIC EVALUATION OF SECOND LINE ORAL ANTIDIABETICS FOR TYPE 2 DIABETES IN COLOMBIA

Quitian H<sup>1</sup>, Aschner P<sup>1</sup>, Muñoz O<sup>1</sup>, Iragorri N<sup>1</sup>, Giron D<sup>1</sup>, Gomez-Restrepo C<sup>1</sup>, Rosselli D<sup>2</sup>

<sup>1</sup>Pontificia Universidad Javeriana, Bogota, Colombia, <sup>2</sup>Pontificia Universidade Javeriana, Bogotá, Colombia

**OBJECTIVES:** Establish incremental cost-effectiveness ratio (ICER) in cost per additional patient with glycemic control for all the oral antidiabetic medications available in Colombia, as a second-line treatment for adult patients with type 2 diabetes (DM2), who do not reach therapeutic targets with metformin and are not yet considered candidates for insulin therapy. **METHODS:** Oral antidiabetic medications were divided into drug classes: sulphonylureas (divided between glibenclamide, other sulphonylureas), thiazolidinediones, GLP-1 receptor agonists, and DPP4 inhibitors. A systematic review of the literature was done to obtain transition probabilities in a Markov model (monthly cycles, time horizon one year) designed to represent the Colombian health system perspective. The main outcome considered was glycemic control, but data on adherence and adverse events were also collected. Costs (in 2014 Colombian pesos; 1 euro = COP 2,660) were estimated from base cases obtained from multidisciplinary expert panel meetings, with local costs applied from national tariff manuals and official drug price registries. Sensitivity analyses were performed. **RESULTS:** Annual treatment costs ranged from € 116 for glibenclamide, and € 98 for other sulphonylureas, to € 12,205 for GLP-1 receptor agonists. Number of patients with glycemic control (per 1000) were glibenclamide 145, sulphonylureas 265, thiazolidinediones 472, GLP-1 receptor agonists 326, and DPP4 inhibitors 417: Compared against other sulphonylureas, glibenclamide was dominated, while ICERs per additional patient with glycemic control per year would be € 516 for DPP-4 inhibitors, € 712 for thiazolidinediones and € 66,790 for GLP-1 receptor agonists. Critical variables in the sensitivity analyses were drug costs (particularly for GLP-1 receptor agonists), but also patient